Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1.

Biomed Pharmacother. 1999 Mar;53(2):73-86. Unique Identifier : AIDSLINE MED/99269755
Shafer RW; Vuitton DA; Division of Infectious Diseases and Geographic Medicine, Stanford; University, CA 94305, USA.

Abstract: Highly active antiretroviral therapy (HAART) refers to a broad category of treatment regimens usually comprised of three or more antiretroviral drugs that, in previously untreated HIV-1-infected patients, are expected to reduce plasma virus levels below the limits of detection. Most HAART regimens include drugs from at least two of the three classes of antiretroviral therapy (nucleoside analog reverse transcriptase (RT) inhibitors, non-nucleoside analog RT inhibitors, and protease inhibitors). In deciding when to initiate antiretroviral therapy, physicians and their patients must balance the virological and immunological benefits of early treatment with the costs of drug therapy, the risk of drug side effects, and the risk of drug resistance if adherence is suboptimal. In previously untreated patients, HIV-1 replication can be suppressed indefinitely with certain HAART regimens. In previously treated patients, the benefits of HAART are often significantly diminished.

Keywords: JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL Anti-HIV Agents/*THERAPEUTIC USE Drug Therapy, Combination Human HIV Infections/*DRUG THERAPY HIV Protease Inhibitors/*THERAPEUTIC USE *HIV-1/DRUG EFFECTS Reverse Transcriptase Inhibitors/*THERAPEUTIC USE
990930
A9991291

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .